<div>
  <ul>
    <li>
      <p>
        Quebec-based AI biotechnology company Congruence Therapeutics has raised an additional USD 15 million in its extended Series A funding round, bringing the total Series A funds to USD 65 million (the previous Series A round closed in February 2022). The extension was led by ​​new investor BDC Capital's Thrive Venture Fund, with participation from existing investors Amplitude Ventures and OrbiMed, among others.
      </p>
    </li>
    <li>
      <p>
        The proceeds will be directed toward further developing the company&rsquo;s Revenir platform and advancing its therapeutic programs towards the clinic. 
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.newswire.ca/news-releases/congruence-therapeutics-announces-close-of-series-a-extension-bringing-total-round-to-over-us-65-million-815960217.html">
      Canada Newswire
    </a>
  </p>
  <p>
    <a href="https://www.finsmes.com/2023/03/congruence-therapeutics-closes-extension-funding-closes-over-us65m-series-a.html">
      FinSMEs
    </a>
  </p>
  <p>
    <a href="https://betakit.com/drug-discovery-startup-congruence-therapeutics-closes-20-million-cad-extension-of-series-a/">
      BetaKit
    </a>
  </p>
  <p>
  </p>
</div>


All Updates

Congruence Therapeutics raises USD 15 million in extended Series A

Congruence Therapeutics raises USD 50 million Series A